catalinagarcia's blog

Antibodies, the extraordinary proteins that serve as the frontline troops of the human immune system, have recently gained attention for their ability to combat tiny compounds known as haptens. Because of their small size, these elusive targets present particular difficulty for the immune system to identify as foreign invaders. However, researchers' inventiveness has resulted in the creation of several techniques to bypass this barrier and unleash the full potential of hapten antibodies.

 

The search for hapten antibodies has been accompanied by a slew of novel techniques, injecting a burst of creativity into the field. To increase immunogenicity, one technique involves connecting haptens to bigger carrier molecules such as proteins or polymeric materials. Adjuvants, which operate as immune system enhancers, are another strategy used to stimulate a more robust response. Furthermore, anti-hapten antibodies, a subset of antibodies that recognize and bind to haptens, have emerged as a potent tool in the search for hapten-specific antibodies.

 

Hapten-specific antibodies offer a wide range of uses, ranging from biotechnology to diagnostics and therapies. One of the most interesting areas is the development of small-molecule antibody therapies, a new class of antibodies designed to target and neutralize disease-causing small-molecules. These small-molecule antibodies have distinct advantages over standard small-molecule medications, including increased specificity and affinity for their targets, which reduces the likelihood of off-target effects and increases efficacy.

 

With the growing demand for small-molecule antibody therapies, specialist services that offer custom antibody generation against a wide range of small compounds have emerged. Creative Biolabs is a US-based biotech company that specializes in small-molecule antibody design and development and can provide a series of services related to small-molecule antibodies. These services use a potent combination of immunization and screening approaches to create antibodies with exceptional specificity and affinity for the target. The resulting antibodies can then be fine-tuned for a wide range of applications, from in vitro diagnostics to therapeutic treatments, opening up a world of possibilities for researchers.

 

Finally, the development of hapten-specific antibodies has sparked a surge of innovation in the fields of small-molecule antibody therapies and diagnostics, holding enormous potential for the detection and treatment of a wide range of disorders. Access to these cutting-edge tools has been democratized by the availability of specialist small-molecule antibody development services, allowing researchers and enterprises to adapt antibodies to their unique needs. As the research progresses, the potential for small-molecule antibodies to make even larger strides in the near future grows.

Therapeutics based on macromolecular proteins and peptides have successfully been efficiently applied to treat serious human diseases. With the development of biotechnologies, a great number of authorized protein therapeutics and drug products have been utilized in clinical research over the last few decades. However, the main issue that needs to be resolved currently for protein therapeutics is the short half-lives caused by fast degradation in serum and quick elimination during clinical application due to enzymatic degradation, renal clearance, liver metabolism, and immunogenicity.

 

After putting in a lot of effort over the years, researchers have discovered some effective strategies for extending the half-life of protein therapeutics and biopharmaceutical products, such as polymers in drug half-life extension. Polymer conjugation is one of the widely used and efficient techniques in drug half-life extension research, and PEGylation in drug half-life extension is an efficient method for improving pharmacokinetic properties owing to its highly hydrophilic and mostly non-toxic features.

 

As protein engineering technology advances, bioactive natural protein conjugation, due to its lower toxic side effects, is becoming more accepted as a competitive method to prolong the half-life of drugs. Currently, diverse technologies of bioactive natural protein conjugation are being developed for the half-life extension of drug research, including:

* Albumin-based half-life extension

Albumin conjugation has been extensively used in a variety of protein drugs on the market.

* Fc-Fusion-based half-life extension

The Fc-Fusion technique works well for most therapeutic protein modifications.

* Transferrin fusion-based half-life extension

Transferrin fusion, a novel method to realize half-life extension, has potential clinical application.

 

In addition, lack of efficacy continues to be a major driver of drug candidate attrition. The drug half-life assay, as the first essential step in drug development to determine the half-life of drugs, is an essential strategy for selecting suitable drug candidates for clinical trials. In this case, many CRO companies are working hard to provide a variety of assays for improving the evaluation of drug candidates, as did Creative Biolabs. Having updated their advanced and comprehensive half-life assay platform, they are confident in providing high-quality half-life assay services to global customers, including but not limited to drug half-life in vitro and in vivo detection services.

 

Creative Biolabs, as a global CRO company focusing on drug development for years, has accumulated extensive experience in half-life extension and won a prominent reputation from customers all over the world. Scientists at Creative Biolabs continue to improve its half-life extension technologies in order to provide customers with the best drug half-life extension services, contributing to accelerating drug development.

Cancer has been a leading cause of death worldwide for decades, accounting for nearly one in every six deaths and posing a serious threat to people's health. A great number of plans and approaches have been approved to support the improvement of cancer cure rates with ongoing research on cancer treatment.

 

A recent study demonstrated that γδ T-cells were found to be the most prognostically beneficial immune cell subset in tumor infiltrates from 18,000 tumors across 39 malignancies, which makes γδ T-cells a kind of highly promising effector cell compartment for cancer immunotherapy. At present, γδ T cells have indicated powerful anti-tumor efficacy against breast cancer, colon cancer, lung cancer, leukemia, and others.

 

As innate immune cells, indeed, gamma delta T cells can recognize tumor cells independently of human leukocyte antigen (HLA) restriction and quickly produce abundant cytokines and potent cytotoxicity in response to malignancies. Gamma delta T cells have several favorable features for the development of T cell-based therapy for cancer, which are listed below:

* Gamma delta T cells recognize a broad spectrum of antigens on various cancer cells.

* Gamma delta T cells recognize their target cells independent of the major histocompatibility complex (MHC).

* Gamma delta T cells are distributed in various tissues and can quickly respond to target tumor cells.

* Gamma delta T cells interact with other immune cells such as B cells to drive a cascade of immune responses against tumors.

 

Isolating and purifying functional and specific gamma delta T cell populations from a complex biological sample is crucial for understanding the biological function of gamma delta T cells and creating gamma delta T cell-based therapies. Therefore, outstanding technologies for T cell isolation play a critical role. Magnetic bead cell sorting (MACS) is a frequent, efficient, and quick method for isolating uncontaminated gamma delta T lymphocytes from human peripheral blood mononuclear cells (PBMCs).

 

In addition, due to the essential function of gamma delta T cells in several diseases, a T cell cytotoxicity test is necessary for testing gamma delta T cell activity and cytotoxicity. The normal cytotoxicity tests include the LDH cytotoxicity test, flow cytometry-based cytotoxicity test, and impedance-based label-free real-time cytotoxicity assay, in which the LDH cytotoxicity test is one of the most commonly used methods for cell cytotoxicity detection.

 

Creative Biolabs is a biotechnology business that focuses on the discovery of gamma delta T cells to combat human cancers. They established and optimized robust platforms in-house for the selective isolation and expansion of anticancer gamma delta T cell populations from human tissues. Furthermore, they offer preclinical research services to assess the safety and efficacy of gamma delta T cell-based cancer immunotherapy.